| O P E N |
ACCR GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| LUNGMAP Screening Protocol Registrations | |||||||||||
| Total | 3697 | 244 | 130 | 70 | 29 | 2 | 02/06/2019 | 444 | 185 | ||
| Screened at PD | 1296 | 79 | 49 | 32 | 14 | 1 | |||||
| Pre-Screened prior to PD | 2392 | 156 | 72 | 33 | 12 | 1 | |||||
| Treatment-naive | 9 | 9 | 9 | 5 | 3 | 0 | |||||
| ctDNA Specimen Submission | 315 | 0 | 0 | 0 | 0 | 0 | |||||
| Re-analysis Requests | 508 | 40 | 10 | 5 | 1 | 0 | |||||
| Sub-Study Assignments | |||||||||||
| LUNGMAP Sub-Study Assignments | 1939 | 212 | 185 | 51 | 21 | 3 | |||||
| Screened at PD | 1068 | 89 | 76 | 30 | 13 | 2 | |||||
| Pre-Screened prior to PD | 807 | 111 | 97 | 16 | 5 | 0 | |||||
| Treatment-naive | 9 | 9 | 9 | 5 | 3 | 1 | |||||
| After PD on a Lung_MAP Sub-Study | 55 | 3 | 3 | 0 | 0 | 0 | |||||
| Sub-Study Assignments (open studies only) | |||||||||||
| S1800E | 166 | 166 | 166 | 43 | 18 | 2 | |||||
| S1900G | 31 | 11 | 4 | 1 | 0 | 0 | |||||
| S1900J | 12 | 12 | 3 | 1 | 0 | 0 | |||||
| S1900K | 20 | 15 | 12 | 6 | 3 | 1 | |||||
| Sub-Study Registrations | |||||||||||
| LUNGMAP Sub-Study Registrations | 518 | 33 | 23 | 15 | 7 | 2 | |||||
| Initial sub-study registrations | 506 | 33 | 23 | 15 | 7 | 2 | |||||
| Subsequent sub-study registrations | 12 | 0 | 0 | 0 | 0 | 0 | |||||
| Patients Registered to a Sub-Study (open studies only) | |||||||||||
| S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab | 378 | 10 | 10 | 10 | 10 | 6 | 2 | 05/22/2025 | 286 | 90 | |
| Docetaxel plus Ramucirumab | Y | 5 | 5 | 5 | 5 | 3 | 1 | ||||
| Cemiplimab plus Docetaxel and Ramucirumab | Y | 5 | 5 | 5 | 5 | 3 | 1 | ||||
| S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | 66 | 21 | 8 | 4 | 1 | 0 | 0 | 05/05/2023 | 285 | 104 | |
| Capmatinib + Osimertinib + Ramucirumab | Y | 11 | 5 | 3 | 1 | 0 | 0 | ||||
| Capmatinib + Osimertinib | Y | 10 | 3 | 1 | 0 | 0 | 0 | ||||
| S1900J: MET Amplification: Amivantamab-SC | 88 | 2 | 2 | 1 | 0 | 0 | 0 | 11/19/2024 | 197 | 75 | |
| Amivantamab SC | Y | 2 | 2 | 1 | 0 | 0 | 0 | ||||
| S1900K: MET Exon 14: Tepotinib +/- Ramucirumab | 56 | 11 | 11 | 8 | 4 | 1 | 0 | 08/08/2024 | 267 | 87 | |
| Tepotinib + Ramucirumab | Y | 8 | 8 | 6 | 3 | 1 | 0 | ||||
| Tepotinib | Y | 3 | 3 | 2 | 1 | 0 | 0 | ||||